Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Penumbra makes the instruments that pull a clot out of a vessel mechanically instead of dissolving it with a drug.
In a stroke or a thrombosis minutes count, and drugs do not always work and not on every clot. A catheter that aspirates the clot restores blood flow immediately and where medication cannot. That changed the standard of care and created a market that did not exist before.
Demand is limited not by need but by throughput: the procedure must be performed by a trained physician in a clinic with the right equipment, and such centres are still too few. Training physicians is therefore the main growth lever. Risks: insurer reimbursement decisions, competition from large medical device makers and clinical trial results. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Penumbra, Inc. (PEN) is a company in the Health care sector; its shares trade on NYSE.
The price of Penumbra, Inc. (PEN) on October 30, 2026 is 319.15 $, −0.88 % on the day. Over 52 weeks the stock traded between 221.26 $ and 362.41 $; the price now sits 69 % of the way up that range. Over the past year the price changed by +27.15 %. The P/E ratio is 77.96, which is above the sector median (24.61). Market capitalization is 12.52 billion $, rank 11 among 100 stocks of the same industry with a known capitalization.
Penumbra, Inc. trades on NYSE under the ticker PEN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks PEN has traded between 221.26 $ and 362.41 $. As of 30 October 2026 the price stood 70.80 % of the way from the 52-week low to the high.
Over one year PEN shares rose 27.15 %; over six months they fell 3.10 %. Volatility over 90 days is 6.03 %. Dividends are not included: this is price change only, as of 30 October 2026.
PEN trades at a price-to-earnings ratio of 78.0, above the sector median of 24.6. Price to sales is 8.3, above the sector median of 3.6. Price to book is 8.2, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Penumbra, Inc. reported revenue of 1.5B $ and net income of 161M $ over the last four quarters. Net margin is 10.67 %. Revenue changed by +17.55 % year over year. Earnings per share are 4.07 $. Market capitalisation is 12.5B $.
PEN has a return on equity of 10.49 %, above the sector median of −40.58 %. Return on assets is 8.13 %, above the sector median of −30.08 %. Operating margin is 12.45 %, above the sector median of −20.96 %.